公开(公告)号：US11078275B2

公开(公告)日：2021-08-03

申请号：US16240906

申请日：2019-01-07

Applicant: INNATE PHARMA

Inventor： Cecile Bonnafous ,  Helene Sicard ,  Renaud Buffet

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US10174112B2

公开(公告)日：2019-01-08

申请号：US15623572

申请日：2017-06-15

Applicant: INNATE PHARMA

Inventor： Cecile Bonnafous ,  Helene Sicard ,  Renaud Buffet

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US11970535B2

公开(公告)日：2024-04-30

申请号：US17114835

申请日：2020-12-08

Applicant: INNATE PHARMA

Inventor： Carine Paturel ,  Helene Sicard

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/3061 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.